277 related articles for article (PubMed ID: 15192796)
21. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
Liu CJ; Kao JH; Chen PJ; Chen TC; Lin FY; Lai MY; Chen DS
J Viral Hepat; 2006 Jun; 13(6):387-95. PubMed ID: 16842441
[TBL] [Abstract][Full Text] [Related]
22. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.
Ijaz S; Arnold C; Dervisevic S; Mechurova J; Tatman N; Tedder RS; Naoumov NV
J Med Virol; 2008 Jul; 80(7):1160-70. PubMed ID: 18461609
[TBL] [Abstract][Full Text] [Related]
23. Suppression of lamivudine-resistant B-domain mutants by adefovir dipivoxil in the woodchuck hepatitis virus model.
Jacob JR; Korba BE; Cote PJ; Toshkov I; Delaney WE; Gerin JL; Tennant BC
Antiviral Res; 2004 Aug; 63(2):115-21. PubMed ID: 15302140
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
25. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
Suzuki F; Kumada H; Nakamura H
J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
[TBL] [Abstract][Full Text] [Related]
26. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus.
Tamori A; Enomoto M; Kobayashi S; Iwai S; Morikawa H; Sakaguchi H; Habu D; Shiomi S; Imanishi Y; Kawada N
J Viral Hepat; 2010 Feb; 17(2):123-9. PubMed ID: 19674281
[TBL] [Abstract][Full Text] [Related]
27. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
Van Bömmel F; Schernick A; Hopf U; Berg T
Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
[No Abstract] [Full Text] [Related]
28. Adefovir dipivoxil to prevent exacerbation of lamivudine-resistant hepatitis B infection during chemotherapy for non-Hodgkin's lymphoma.
Enomoto M; Nishiguchi S; Seki S; Yamane T; Hino M
Am J Gastroenterol; 2004 Aug; 99(8):1619-20. PubMed ID: 15307884
[No Abstract] [Full Text] [Related]
29. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.
Zhang WX; Lai V; Mutimer D; Mirza D
Hepatobiliary Pancreat Dis Int; 2006 Feb; 5(1):154-6. PubMed ID: 16481305
[TBL] [Abstract][Full Text] [Related]
30. [A study on the treatment of chronic hepatitis B with YMDD mutation].
Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
[TBL] [Abstract][Full Text] [Related]
31. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
[TBL] [Abstract][Full Text] [Related]
32. The risk of adefovir monotherapy in human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infected patients.
Gelinck LB; Claas EC; Kroon FP
J Hepatol; 2005 Aug; 43(2):360-1; author reply 361. PubMed ID: 15970350
[No Abstract] [Full Text] [Related]
33. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
[TBL] [Abstract][Full Text] [Related]
34. [The clinical study of adding on adefovir dipivoxil to treat for lamivudine resistant patients with chronic hepatitis B].
DING JG; SUN QF; FU RQ; WU YH; HONG L
Zhonghua Gan Zang Bing Za Zhi; 2009 May; 17(5):387-8. PubMed ID: 19497209
[No Abstract] [Full Text] [Related]
35. [Current treatment of hepatitis B].
Suárez García E; Romero Gómez M; Grande Santamaría L
Gastroenterol Hepatol; 2001 Feb; 24 Suppl 1():35-50. PubMed ID: 11279893
[No Abstract] [Full Text] [Related]
36. Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus.
Herreros de Tejada Echanojáuregui A; Moreno Planas JM; Rubio González E; Portero Azorin F; López Monclús J; Revilla Negro J; Lucena de la Poza JL; Sánchez Turrión V; Barrios Peinado C; Cuervas-Mons Martínez V
Transplant Proc; 2005 Apr; 37(3):1507-8. PubMed ID: 15866657
[TBL] [Abstract][Full Text] [Related]
37. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir.
Ong A; Wong VW; Wong GL; Chan HY; Tse CH; Chan HL
Aliment Pharmacol Ther; 2011 Oct; 34(8):972-81. PubMed ID: 21883327
[TBL] [Abstract][Full Text] [Related]
38. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
[TBL] [Abstract][Full Text] [Related]
39. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
[TBL] [Abstract][Full Text] [Related]
40. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance.
Kim YJ; Paik SW; Sinn DH; Gwak GY; Choi MS; Lee JH; Koh KC; Yoo BC
J Gastroenterol Hepatol; 2012 Sep; 27(9):1454-60. PubMed ID: 22168753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
